GlenmarkPharma Gains 4% On USFDA Approval For Anti-Anginal Drug.

GlenmarkPharma Gains 4% On USFDA Approval For Anti-Anginal Drug.

Tuesday, July 09, 2019
Glenmark Pharmaceuticals shares rallied 3.6 percent intraday on July 9 after the company received approval from US health regulator for anti-anginal drug.

The US Food and Drug Administration granted its approval for Ranolazine extended-release tablets, which will be available in 500 mg and 1,000 mg strengths.

Ranolazine is a generic version of Ranexa extended-release tablets of Gilead Sciences, Inc. The drug improves blood flow to help the heart work more efficiently.

For more information on Stock Tips For Tomorrow Nifty Call Option

and quick free trial click here > 911 133 9000

Visit http://www.epicresearch.co
Connect with our social media sites
Next
« Prev Post
Previous
Next Post »